Asia-Pacific Point-of-Care Diagnostics Market by Application (Influenza, Pneumonia, HAI, Salmonellosis, Hepatitis, HIV, COVID, Pregnancy, Glucose Monitoring, Hematology, Tumor Marker, Urinalysis), Platform (LFA, Molecular), Sample, End User - Forecast to 2030

The Asia-Pacific Point-of-Care Diagnostics Market is projected to reach $11.80 billion by 2030, at a CAGR of 7.5% from 2024 to 2030. Point-of-Care diagnostics (PoC diagnostics), also known as bedside or near-patient testing, refers to medical diagnostic testing conducted near the patient, typically at the location where healthcare is provided. The key characteristic of PoC diagnostics is the ability to deliver rapid results, often within minutes, allowing healthcare providers to make immediate treatment decisions or recommendations based on the test outcomes.

The growth of this market is driven by the increasing prevalence of chronic diseases, innovations in PoC tests, and a lack of skilled technicians for performing lab tests. However, the pricing pressure due to fluctuations in reimbursements restrains the market’s growth. Furthermore, healthcare professionals’ increasing preference for PoC tests over lab tests will offer significant market growth opportunities. However, a lack of awareness regarding the use of PoC devices challenges the market’s growth.

Lack of Skilled Technicians for Performing Lab Tests Drives the Point-of-Care Diagnostics Market

The demand for pathology services has grown significantly in recent years and is expected to grow further during the forecast period. However, the pathology workforce has not increased in line with this demand. Delays in initial diagnosis can lead to delays in treatment. The workforce shortage can be attributed to aging and retiring professionals and the lack of adequate histology programs to train enough new entrants.

According to Medical Futurist, by 2030, the number of active pathologists may drop by 30% compared to 2010 levels. The Chinese Pathologist Association states that there are only 20,000 licensed pathologists in China, a country with a population of over 1.4 billion. Furthermore, there is a growing need for clinical laboratory workers due to their acute shortage. Factors such as laboratory professionals retiring or leaving the profession, the increasing demand for laboratory services, and changes in clinical laboratory science practices due to technological advances contribute to this shortage of skilled professionals. This shortage disrupts the delivery of healthcare services, impacting patients and healthcare providers. Thus, the shortage of skilled professionals leads to delays in diagnosis and treatment, leading to an increased reliance on self-testing. These factors are boosting the adoption of PoC diagnostics, driving the growth of this market.

Click here to: Get Free Sample Pages of this Report

Healthcare Professionals’ Increasing Preference For PoC Tests Over Lab Tests Create an Opportunity for Market Growth

Many healthcare professionals in hospitals and clinical laboratories prefer using point-of-care diagnostics to diagnose various health conditions promptly. Healthcare professionals are replacing established diagnostic methods (microscopy, pathogen culturing, biochemical testing, conventional polymerase chain reaction (PCR), enzyme-linked immunoassay (ELISA), and other time-consuming diagnostic methods) with new point-of-care diagnostic techniques that provide higher levels of efficiency and reproducibility. As point-of-care diagnostics have superior utility, experts are changing their traditional approaches. This acceptance of point-of-care diagnostics is supporting the research & development efforts of clinical laboratories and other health-services companies in the diagnostics industry. This inclination towards point-of-care methods and practices among physicians drives the growth of the point-of-care diagnostics market.

Key Findings of the Asia-Pacific Point-of-Care Diagnostics Market Study:

In 2024, the Consumables Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

Among the offerings included in the report, in 2024, the consumables segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. Factors such as the increasing number of immunoassay and molecular diagnostics tests being performed globally, leading to recurrent purchases of kits and reagents, rise in product approvals, and technological advancements in PoC testing are contributing to the large share of this market.

In 2024, the Blood Sample Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

Among the sample types included in the report, in 2024, the blood sample segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. The large market share of this segment is attributed to the availability of a large variety of tests using blood samples, increasing prevalence of various chronic diseases, and increasing consumer awareness regarding the monitoring of chronic diseases.

In 2024, the Blood Glucose Monitoring Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

Among the applications included in the report, in 2024, the blood glucose monitoring segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. The large market share of this segment is attributed to the rising prevalence of diabetes and the growing need for blood glucose monitoring. For instance, according to the International Diabetes Federation (IDF), in Southeast Asia, the number of adults with diabetes is estimated to reach 113 million by 2030 from 90 million in 2021.

In 2024, the Lateral Flow Assays Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

Among the platforms included in the report, in 2024, the lateral flow assays segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. Lateral flow assays are simple one-step assays that are low-cost devices. The major factors contributing to this segment's largest share are the growing prevalence of chronic and infectious diseases, technological innovations, and the advantages of lateral flow assays, such as cost-effectiveness and rapid results.

In 2024, the Hospitals Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

Among the end users included in the report, in 2024, the hospitals segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market. The rising number of hospitals and clinics, increasing demand for point-of-care diagnostics, and increasing healthcare expenditure worldwide are driving the demand for PoC diagnostics. Furthermore, the outbreak of the COVID-19 pandemic has resulted in an increased demand for PoC diagnostic kits in hospitals & clinics for the treatment and prevention of COVID-19 infections.

China: Fastest-growing Country-level Market

Based on geography, China is slated to record the highest growth rate during the forecast period. The rising prevalence of infectious & chronic diseases, the growing aging population, and the increasing adoption of self-testing mainly drive the growth of this market. Healthcare spending in China has shown year-on-year growth. According to The World Bank Group, the health expenditure (% of GDP) increased from 4.94% in 2015 to 5.59% in 2020.

Key Players

The key players profiled in this market study are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).

Scope of the Report:

Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Offering

• Consumables
• Instruments
• Software and Services

Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Platform

• Lateral Flow Assays
• Molecular Diagnostics
• Other Platforms
  (Note: Other Platforms include coagulation tests, dipsticks, cholesterol and glucose monitoring systems, and other point-of-care diagnostic platforms)

Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Application

• Blood Glucose Monitoring
• Infectious Disease Testing
  • Parasitic Infections Testing    
  • Blood-Borne Infections Testing
    • Hepatitis
    • HIV
    • Other Blood-Borne Infections
      (Note: Other Blood-borne Infections include syphilis and brucellosis)
  • Respiratory Infections Testing
    • Influenza
    • Pneumonia
    • Tuberculosis (TB)
    • Other Respiratory Infections Testing
      (Note: Other Respiratory Infections Testing include strep infections and respiratory syncytial virus (RSV))
  • Healthcare-Associated Infection (HAI) Testing
  • Gastrointestinal Infections Testing
    • Salmonellosis
    • E. Coli Infections
    • Other GI Infections
      (Note: Other GI Infections Testing include cholera, Helicobacter pylori (H. pylori), and campylobacteriosis)
  • Other Infectious Diseases Testing
    (Note: Other Infectious Diseases Testing include meningitis, hand, foot, and mouth disease (HFMD), and mononucleosis)
• COVID-19 Testing
• Tumor/Cancer Markers Testing
• Pregnancy and Fertility Testing
  • Pregnancy Testing
  • Fertility Testing
• Cardiac Marker/Cardiac Metabolism Testing
• Cholesterol/Lipid Profile Testing
• Coagulation Testing
  • Prothrombin Time (PT/INR) Testing
  • Activated Clotting Time (ACT/APTT) Testing
  • Other Coagulation Testing
    (Note: Other Coagulation Testing include fibrinogen level and platelet count)
• Hematology
• Drugs of Abuse Testing
• Urinalysis
• Other PoC Testing
  (Note: Other PoC Testing includes tropical diseases and sexually transmitted diseases)

Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Sample Type

• Blood Sample
• Nasopharyngeal Swab
• Urine Sample
• Saliva Sample
• Other Sample Types
  (Note: Other Sample Types include stool, cervical swab, buccal swab, hair, vaginal swab, and semen)

Asia-Pacific Point-of-Care Diagnostics Market Assessment, by End User

• Hospitals
• Home Care/Self-Testing
• Physician Offices & Ambulatory Care Settings
• Diagnostics Laboratories
• Other End Users
  (Note: Other End Users include nursing homes, long-term care centers, pharmacies, urgent care facilities, schools, airports, hotels, and workplaces)

Asia-Pacific Point-of-Care Diagnostics Market Assessment, by Geography

• Japan
• China
• India
• South Korea
• Australia
• New Zealand
• Singapore
• Thailand
• Rest of Asia-Pacific (RoAPAC)

Key questions answered in the report: